SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

Investors are actively debating the legitimacy of a tokenized crypto asset claiming to represent SpaceX, with many warning it is a scam while others speculate on its connection to the company's long-rumored IPO. The community conversation is dominated by intense skepticism regarding unauthorized tokens, contrasted with broader market excitement surrounding SpaceX's expected public debut and its potential impact on space-sector stocks.

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as investors highlight its role as an AI-powered infrastructure project on the Base ecosystem, with community members actively discussing its long-term potential as an undervalued asset. The sentiment is fueled by consistent development updates from the team and strong ecosystem volume, leading many to hold through market volatility in anticipation of future price appreciation.

Swell

The community is actively debating the potential of Swell, with supporters highlighting its liquid staking utility, institutional backing, and low market cap as key drivers for long-term growth. Conversely, critics frequently dismiss the asset as a speculative project, pointing to recurring price volatility and concerns over supply issuance as reasons for caution.

Uranium Energy Corp. engages in the provision of uranium and titanium mining and related activities, including exploration, pre-extraction, extraction, and processing of uranium concentrates, and titanium minerals. It operates through the following geographical segments: Wyoming, Texas, Saskatchewan, and Others. The company was founded by Alan P. Lindsay and Amir Adnani on May 16, 2003 and is headquartered in Corpus Christi, TX.

Uranium Energy Corp

Uranium Energy Corp is trending as investors focus on its U.S.-based ISR production ramp-up, with community discussions highlighting its potential to capture rising demand from AI-driven data center power needs. The stock is seeing heavy attention amid a broader nuclear energy narrative, as market participants monitor institutional accumulation and upcoming earnings in anticipation of a potential sector-wide squeeze.

Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company was founded by Tadataka Yamada, David Socks, Azmi Nabulsi, Aditya Kohli, and Roger Ulrich on January 9, 2018 and is headquartered in Florham Park, NJ.

Phathom Pharmaceuticals Inc

Phathom Pharmaceuticals is trending as investors monitor institutional accumulation and signs of a potential short squeeze amid anticipation of profitability in the coming quarters. The community is actively discussing the drug's strong prescription growth and its long-term potential as an acquisition target for larger pharmaceutical firms.

Evolution Metals & Technologies Corp. engages in developing a global supply chain for critical minerals and materials. It focuses on automotive, renewable energy, and military and defense sectors. The company is headquartered in West Palm Beach, FL.

Evolution Metals & Technologies Corp.

Evolution Metals & Technologies Corp. Common Stock

Evolution Metals & Technologies Corp. (EMAT) is gaining momentum as investors weigh its potential as a vertically integrated domestic rare earth magnet manufacturer against concerns regarding its micro-float and high insider ownership. Community discussion is split between excitement over the stock's positioning as a strategic alternative to foreign supply chains and caution regarding its characteristic high volatility and potential for sharp price swings.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following an exclusive U.S. supply agreement for the Tokyo strain of BCG to address the ongoing domestic shortage, a move the community views as a strategic breakthrough that strengthens the company's competitive position against major pharmaceutical players. Investors are actively discussing the potential for accelerated regulatory pathways, the synergy between this supply and Anktiva, and the anticipation of further catalysts being revealed at the upcoming American Urological Association conference.

PDD Holdings, Inc. is a multinational commerce group that owns and operates a portfolio of businesses. The company aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from increased productivity and new opportunities. It has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses. PDD Holdings was founded by Hua Lin Cai and Zheng Huang in 2015 and is headquartered in Dublin, Ireland.

PDD Holdings Inc - ADR

Pinduoduo Inc.

Pinduoduo is seeing high volatility as investors balance strong earnings-driven growth potential with significant competitive pressures and ongoing regulatory scrutiny. The community is actively debating the stock's long-term value, with many traders closely monitoring high-volume options activity for signs of a breakout.

Freeport-McMoRan, Inc. engages in the mining of copper, gold, and molybdenum. It operates through the following segments: U.S. Copper Mines, South America Operations, Indonesia Operations, Molybdenum Mines, U.S. Rod and Refining, Atlantic Copper, and Corporate and Other. The U.S. Copper Mines segment operates open-pit copper mines in Morenci, Bagdad, Safford, Sierrita, Miami in Arizona and Chino, and Tyrone in New Mexico. The South America Operations segment includes Cerro Verde in Peru and El Abra in Chile. The Indonesia Operations segment handles the operations of the Grasberg minerals district that produce copper concentrate containing significant quantities of gold and silver. The Molybdenum Mines segment includes the Henderson underground mine and Climax open pit mine, both in Colorado. The U.S. Rod and Refining segment consists of copper conversion facilities located in North America and includes refinery and rod mills. The Atlantic Copper segment smelts and refines copper concentrate and markets refined copper and precious metals in slimes. The Corporate and Other segment offers other mining and eliminations, oil and gas operations, and other corporate and elimination items. The company was founded by James R. Moffett on November 10, 1987, and is headquartered in Phoenix, AZ.

Freeport-McMoRan Inc

Freeport-McMoRan is attracting significant attention as investors position for a long-term copper supercycle driven by rising demand from AI infrastructure, electrification, and data center expansion. The community is actively monitoring supply chain constraints and Grasberg mine recovery efforts, while institutional interest remains high as market participants track recent price breakouts and supply-demand imbalances in the global copper market.

Ideal Power, Inc. engages in the development of power converter solutions for photovoltaic generation, grid-storage and electrified vehicle charging. Its products include solar inverters, bi-directional battery, electric vehicle chargers, photovoltaic inverters and battery converters. It is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. The company was founded by William C. Alexander on May 17, 2007 and is headquartered in Austin, TX.

Ideal Power Inc

Ideal Power is trending as investors monitor its progress in commercializing B-TRAN technology, highlighted by the early completion of its first major solid-state circuit breaker design win in Asia. The community is focused on the stock's potential for institutional adoption and institutional validation as it targets a multibillion-dollar market for power semiconductors in data centers, EVs, and renewable energy.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zentalis Pharmaceuticals (ZNTL) to Release Earnings on Wednesday

Zentalis Pharmaceuticals (NASDAQ:ZNTL) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 13. (View Earnings Report at...

Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Grows By 22.2%

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) saw a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 5,204,555...

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been given an average rating of "Hold" by the seven brokerages that are presently covering the company, Marketbeat reports. One...

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 31.4% during the third quarter, according to its most recent filing with the Securities...

Pharmaceutical Stocks To Follow Today - April 10th

Eli Lilly and Company, Abbott Laboratories, Pfizer, AbbVie, Novo Nordisk A/S, Organon & Co., and Zentalis Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

What's Behind The Surge In Zentalis Stock?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.read more...

<ul class="summary-bullets"><li>Zentalis selected the 400 mg dose of its drug to treat ovarian cancer after it showed a higher response rate than the 300 mg dose.</li><li>The company expects to complete enrollment and report topline results from the trial by the end of 2026.</li><li>This comes just two weeks after the FDA approved Cort’s ovarian cancer treatment months ahead of schedule.</li></ul>Shares of Zentalis Pharmaceuticals (ZNTL) soared over 40% on Friday to their highest level since June 2024, after a bullish analyst call highlighted improved efficacy from a higher dose of its ovarian cancer drug while maintaining a comparable safety profile.Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating, according to The Fly. This implies a potential 56% upside from the stock’s current price. The firm cited the price target change to the increased confidence in the drug’s chances of success in platinum-resistant ovarian cancer.<h2 class="st-heading-2">Zentalis Picks 400 MG Dose For Future Trials</h2>On Thursday, Zentalis announced encouraging interim results from its DENALI Part 2a study of Azenosertib, an oral therapy, in platinum-resistant ovarian cancer, supporting the drug’s further late-stage development.The biotech firm selected the 400 mg once-daily dose (five days on, two days off) after it showed a clearly higher response rate than the 300 mg dose, while maintaining a similar safety profile. The 400 mg dose will now be used in the ongoing Phase 2 DENALI trial and the Phase 3 ASPENOVA study.Zentalis expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026.<h2 class="st-heading-2">FDA Approved Corcept’s Ovarian Cancer Drug Months Ahead Of PDUFA Date</h2>The results are crucial, as they allow Zentalis to move towards potential regulatory approval. Just two weeks earlier, the U.S. Food and Drug Administration (FDA) <a href="https://stocktwits.com/news-articles/markets/equity/cort-stock-skyrockets-35-after-early-fda-nod-for-ovarian-cancer-drug/cZ3YMziRISr">approved</a> Corcept Therapeutics’ (CORT) ovarian cancer treatment.The approval covers adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received treatment.Notably, the FDA’s decision came way ahead of schedule, as the therapy had been assigned a Prescription Drug User Fee Act (PDUFA) target date of July 11, 2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ZNTL">ZNTL</a> on Stocktwits changed to ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.One user expects the company’s valuation to explode seven to 10-fold if the drug is successful in monotherapy.<stembedurl>https://stocktwits.com/Lukey63/message/649876699</stembedurl>However, another user said the stock is overvalued, highlighting the company’s pipeline.<stembedurl>https://stocktwits.com/ScorpionScarlet/message/649934768</stembedurl>Year-to-date, the stock has shot up more than 370%.&nbsp;

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally

Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating after the company posted the interim results for its ovarian cancer drug.

ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update

Equity

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00

Guggenheim lifted their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a "buy" rating in a research note on Friday...

These Stocks are Heating Up Fast

Top stocks to trade this afternoon. $ONCO, $KBLB, $ARAI, $EOSE, $ZNTL

Brokers Issue Forecasts for ZNTL FY2030 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Zentalis Pharmaceuticals in a report released on...

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.48	--	--	N/A
Q1 '26	-$0.48	-$0.50	-4.90%	MISSED
Q4 '25	-$0.47	-$0.50	-7.34%	MISSED
Q3 '25	-$0.53	-$0.37	29.90%	BEAT
Q2 '25	-$0.59	-$0.37	37.67%	BEAT

ZNTL
Zentalis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Latest ZNTL News

ZNTLZentalis Pharmaceuticals Inc